High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment

Leukemia

Volumn 17, Issue 3, 2003, Pages 576-584

  Jedema, I ^a   Barge, R M Y ^a   Willemze, R ^a   Falkenburg, J H F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cell cycle; Fas; Immunotherapy; Interferon; Leukemia

Indexed keywords

ALPHA INTERFERON; FAS ANTIBODY; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOLYSIS; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MITOSIS; MYELOID LEUKEMIA; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0037352906     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402844     Document Type: Article

References (25)

1. Liliemark JO, Plunkett W. Regulation of 1-beta-D-arabinofurano-sylcytosine 5′-triphosphate accumulation in human leukemia cells by deoxycytidine 5′-triphosphate. Cancer Res 1986; 46: 1079-1083.
2. van Maanen JM, Retel J, de Vries J, Pinedo HM. Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 1988; 80: 1526-1533.
3. Helg C, Starobinski M, Jeannet M, Chapuis B. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 1998; 29: 301-313.
4. Smit WM, Rijnbeek M, van Bergen CA, Fibbe WE, Willemze R, Falkenburg JH. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 1998; 95: 10152-10157.
5. Falkenburg JHF, Wafelman AR, Joosten P, Smit WM, van Bergen CAM, Bongaerts R et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201-1208.
6. Waring P, Mullbacher A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol 1999; 77: 312-317.
7. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255-260.
8. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
9. Komada Y, Zhou YW, Zhang XL, Xue HL, Sakai H, Tanaka S et al. Fas receptor (CD95)-mediated apoptosis is induced in leukemic cells entering G1B compartment of the cell cycle. Blood 1995; 86: 3848-3860.
10. Beletskaya IV, Nikonova LV, Beletsky IP. Cell cycle specificity of Fas-mediated apoptosis in WIL-2 cells. FEBS Lett 1997; 412: 91-93.
11. Hueber A, Durka S, Weller M. CD95-mediated apoptosis: no variation in cellular sensitivity during cell cycle progression. FEBS Lett 1998; 432: 155-157.
12. Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, Gemperlein I et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 1987; 70: 192-199.
13. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 34-55.
14. Ezaki K. Cytokine therapy for hematological malignancies. Int J Hematol 1996; 65: 17-29.
15. Leda M, Ladon D, Pieczonka A, Boruczkowski D, Jolkowska J, Witt M et al. Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk Res 2001; 25: 353-357.
16. Marijt WAF, Barge RMY, Fibbe WE. Combining alpha-interferon with low dose donor lymphocyte infusion (DLI) for relapsed CML reduces the interval between DLI and complete remission (CR) and is associated with limited GVHD. Blood 2000; 96: 196a (Abstract).
17. Spets H, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon-alpha in interleukin-6 (IL-6)-dependent and IL-6 independent multiple myeloma cell lines. Blood 1998; 92: 2914-2923.
18. Zella D, Barabitskaja O, Casareto L, Romerio F, Secchiero P, Reitz Jr MS et al. Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells. J Immunol 1999; 163: 3169-3175.
19. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 2000; 60: 5673-5680.
20. Jordan CT, Yamasaki G, Minamoto D. High-resolution cell cycle analysis of defined phenotypic subsets within primitive human hematopoietic cell populations. Exp Hematol 1996; 24: 1347-1355.
21. van Oijen MG, Medema RH, Slootweg PJ, Rijksen G. Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol 1998; 110: 24-31.
22. Danova M, Riccardi A, Mazzini G. Cell cycle-related proteins and flow cytometry. Haematologica 1990; 75: 252-264.
23. Landberg G, Tan EM, Roos G. Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle. Exp Cell Res 1990; 187: 111-118.
24. Schwarting R, Gerdes J, Niehus J, Jaeschke L, Stein H. Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67. J Immunol Methods 1986; 90: 65-70.
25. Barge RM, Willemze R, Vandenabeele P, Fiers W, Beyaert R. Differential involvement of caspases in apoptosis of myeloid leukemic cells induced by chemotherapy versus growth factor withdrawal. FEBS Lett 1997; 409: 207-210.